LA Weekly: First FDA Pot for PTSD Study Raises No Safety Concerns

Summary: LA Weekly covers the results of a MAPS-sponsored clinical trial of cannabis for the treatment of posttraumatic stress disorder (PTSD) in Veterans, which raised no safety concerns. The article highlights that “further research is needed, however, with higher quality cannabis, to prove its efficacy,” referencing both the published study and MAPS’ recent press release on the subject.

Originally appearing here.